Astrazeneca: London-listed pharma giant heralds successful breast cancer drug April 29, 2024 Astrazeneca has found that Enhertu helped patients live longer without their breast cancer getting worse compared to standard chemotherapy.
Astrazeneca’s revenue surges as pipeline investments pay off April 25, 2024 Pascal Soriot, chief executive officer of AstraZeneca, said: "Astrazeneca had a very strong start in 2024 with substantial total revenue growth of 19 per cent in the first quarter.
Angle agrees deal with Astrazeneca for tech to kill cancer cells April 24, 2024 This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment.
How much is too much? The CEO pay predicament April 23, 2024 A growing number of London-listed companies have been asking shareholders to approve radical pay rises for their top execs. Why?
Global top 50 companies: UK absent as American tech triumphs April 22, 2024 There are now no UK companies among the top 50 largest listed companies in the world, as the British economy has struggled to compete with the dominance of American tech firms.
Flush FTSE 100 giant Astrazeneca to give more back to shareholders with dividend hike April 11, 2024 AstraZeneca will increase its annual dividend for the year by $0.20 (16p) to $3.10 (£2.47) per share
Are LVMH, Nestle, L’Oreal and Hermes Europe’s alternative to Microsoft, Apple, Nvidia and Tesla? April 9, 2024 Much has been made of the 'Magnificent Seven' tech stocks - Meta, Apple, Amazon. Alphabet, Microsoft, Nvidia and Tesla - which have dominated the US market amid a boom in demand for AI and, until recently, more optimism over potential interest rate cuts.
Covid-19 anniversary: How have GSK and Astrazeneca fared since? March 23, 2024 The Covid-19 pandemic also ignited interest in the pharmaceutical sector. Even before the UK went into lockdown, the sector was looking for ways to fight the virus.
Astrazeneca expands cancer treatment stable with purchase of Canada-based Fusion March 19, 2024 The Cambridge-based pharma firm is paying $2bn cash up front as part of the deal
Astrazeneca: Pharma giant snaps up rare disease biotech firm Amoylt March 14, 2024 The acquisition, which is meant to "bolster" Astrazenca's rare disease arm Alexion, brings with it a Phase III investigational therapeutic peptide meant for hypoparathyroidism